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Abstract
Background: Human or animals lacking either JAK3 or the common gamma chain (gc) expression display severe
combined immunodeficiency disease, indicating the crucial role of JAK3 in T-cell development and the
homeostasis of the immune system. JAK3 has also been suggested to contribute to the pathogenesis of
tumorigenesis. Recent studies identified activating JAK3 mutations in patients with various hematopoietic
malignancies, including acute megakaryoblastic leukemia. Importantly, functional analyses of some of those JAK3
mutations have been shown to cause lethal hematopoietic malignancies in animal models. These observations
make JAK3 an ideal therapeutic target for the treatment of various human diseases. To identify novel small
molecule inhibitors of JAK3, we performed structure-based virtual screen using the 3D structure of JAK3 kinase
domain and the NCI diversity set of compounds.
Results: We identified NSC114792 as a lead compound. This compound directly blocked the catalytic activity of
JAK3 but not that of other JAK family members in vitro. In addition, treatment of 32D/IL-2Rb cells with the
compound led to a block in IL-2-dependent activation of JAK3/STAT5 but not IL-3-dependent activation of JAK2/
STAT5. Consistent with the specificity of NSC114792 for JAK3, it selectively inhibited persistently-activated JAK3, but
failed to affect the activity of other JAK family members and other oncogenic kinases in various cancer cell lines.
Finally, we showed that NSC114792 decreases cell viability by inducing apoptosis through down-regulating anti-
apoptotic gene expression only in cancer cells harboring persistently-active JAK3.
Conclusions: NSC114792 is a lead compound that selectively inhibits JAK3 activity. Therefore, our study suggests
that this small molecule inhibitor of JAK3 can be used as a starting point to develop a new class of drugs
targeting JAK3 activity, and may have therapeutic potential in various diseases that are caused by aberrant JAK3
activity.
Background
The mammalian genomes encode four members of the
JAK family of protein tyrosine kinases, including JAK1,
JAK2, JAK3, and TYK2 [1,2]. In particular, JAK3 is pre-
ferentially expressed in lymphoid cells and mediates sig-
nals through gcs h a r e db yr e c e p t o r sf o rI L - 2 ,I L - 4 ,I L - 7 ,
IL-9 and IL-15, indicating the crucial role of JAK3 in T-
cell development and the homeostasis of the immune
system [3]. Consistent with this observation, human or
animals lacking either JAK3 or gc expression suffer from
severe combined immunodeficiency disease character-
ized by the absence of T and NK cells and the presence
of non-functional B cells [3]. Furthermore, JAK3 has
been shown to be involved in the regulation of mast
cell-mediated allergic and asthmatic responses [4].
Therefore, JAK3 has attracted significant attention in
recent years as a therapeutic target for the treatment of
various immune-related diseases such as autoimmune
disorders and asthma, and for the prevention of organ
allograft rejection [5,6].
In addition to the key role of JAK3 in immune cell
development and function, it has also been suggested to
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studies identified somatic mutations of JAK3 in a minor-
ity of acute megakaryoblastic leukemia patients [7-10],
in a high-risk childhood acute lymphoblastic leukemia
(ALL) case [11], and in cutaneous T-cell lymphoma
patients [12]. Importantly, functional analyses of some
of those JAK3 mutations have been shown to cause
lethal hematopoietic malignancies in animal models [7],
suggesting that those JAK3 mutations contribute to the
pathogenesis of hematopoietic malignancies. In addition,
persistently-activated JAK3 was reported in various cell
lines that were derived from lymphoproliferative disor-
ders, including mantle-cell lymphoma [13], Burkitt lym-
phoma [14], and anaplastic large-cell lymphoma [15-17].
Furthermore, it has been shown that persistently-acti-
vated JAK3 is observed in the mouse model of pre-B-
cell leukemia spontaneously developed by loss-of-func-
tion of the tumor suppressor B-cell linker (BLNK) [18].
BLNK expression has been reported to be lost in 50% of
pediatric B-ALL cases [19]. In addition, BLNK was
shown to be required for direct JAK3 inhibition. These
results suggest that persistent JAK3 activation contri-
butes to the pathogenesis of a certain portion of pedia-
tric B-ALL cases. Interestingly, despite the preferential
expression of JAK3 in hematopoietic cells, persistently-
activated JAK3 has also been reported in colon carci-
noma tumors and cell lines [20], implying the role of
JAK3 in the pathogenesis of solid tumors. In support of
this, a recent study identified somatic JAK3 mutations in
patients with breast carcinomas and gastric carcinoma
[21]. Taken together, these findings make JAK3 an
attractive therapeutic target for the treatment of patients
with hematopoietic malignancies, as well as solid
tumors.
In this study, we performed a small-scale, pilot struc-
ture-based computational database screen using the 3D
s t r u c t u r eo fJ A K 3k i n a s ed o m a i na n dt h eN C Id i v e r s i t y
set of compounds to identify small molecule inhibitors
of JAK3. We identified NSC114792 that potently inhibits
both IL-2-induced and persistently-active JAK3. Impor-
tantly, this compound showed selective inhibition of
JAK3 but not other JAK family members or other onco-
genic kinases.
Results
Identification of NSC114792 through structure-based
virtual screen
To identify novel chemical compounds that inhibit JAK3
activity, we performed structure-based virtual screen
using the 3D structure of JAK3 kinase domain (PDB ID:
1YVJ) and the NCI diversity set, which is a small library
consisting of a collection of about 2,000 synthetic small
molecules selected from the full NCI screening collec-
tion. We modified the conventional docking methods by
generating several conformations of a compound and
then utilizing the ensemble for docking. Our test runs
revealed that the resulting complexes have the lower
binding energies than those obtained by the simple
increment of conformers. Of the compounds that
showed lower binding energies in our virtual screening,
we identified NSC114792 (10,13-dimethyl-17- [2-(6-sul-
fanylidene-3H-purin-9-yl)acetyl]-
1,2,6,7,8,9,11,12,14,15,16,17 dodecahydrocyclopenta [a]
phenanthren-3-one) (Figure 1A) as a potential JAK3
inhibitor due to its specificity for JAK3 over other JAK
family members (see below). Its binding mode in the
docked complex with JAK3 kinase domain is shown in
Figure 1C. The lowest energy structure of NSC114792
displays the contacts in the side chains of Leu-804, Val-
812, Ala-829, Lys-831, Glu-847, Val-860, Met-878, Tyr-
880, Leu-932 and Ala-942 of the kinase domain, indicat-
ing that hydrophobic interaction is dominant. As shown
in overlaid structures of 4ST and NSC114792 with JAK3
kinase domain (Figure 1B), the binding mode of
NSC114792 to the JAK3 kinase domain is distinct from
that of 4ST, where Val-812, Met-878, Tyr-880 and Leu-
932 are considered the major contact sites. This obser-
vation suggests that additional residues around Tyr-880,
Met-878 and Glu-847 in JAK3 kinase domain participate
in binding of NSC114792. The values of dissociation
constant, Kd, calculated by AutoDock energy were 10.64
and 5.44 nM for 4ST and NSC114792, respectively.
NSC114792 directly blocks JAK3 kinase activity
The four mammalian JAKs- JAK1, JAK2, JAK3, and
TYK2 - share significant structural homology, which
prompted us to investigate the specificity of NSC114792
f o rJ A K 3a n d / o rf o ro t h e rJ A K s .W ef i r s tp e r f o r m e din
vitro kinase assays using immunoprecipitates for each
JAK and recombinant STAT3a proteins as a substrate.
JAK1, JAK2, and JAK3 immunoprecipitates were pre-
pared from the lysates of Hodgkin’sl y m p h o m aH D L M -
2 or L540 cells, where persistently-active JAK1 and
JAK2 or JAK3 are expressed, respectively. Immunopreci-
pitates of TYK2 were derived from multiple myeloma
U266 cells following treatment with IFN-a,ak n o w n
activator of TYK2 [22]. Each immunoprecipitate was
incubated with STAT3a p r o t e i ni nt h ea b s e n c eo rp r e -
sence of various concentrations of NSC114792. All JAK
immunoprecipitates were efficiently phosphorylated
STAT3a protein in the absence of NSC114792. How-
ever, the addition of this compound resulted in an inhi-
bition of JAK3 kinase activity in a dose-dependent
manner (Figure 2C), whereas NSC114792 did not affect
the kinase activity of other JAK members at the concen-
trations up to 20 μm o l / L( F i g u r e2 A ,Ba n d2 D ) .A s
expected, the pan JAK inhibitor AG490 blocked the
kinase activity of all four JAKs.
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(V674A) from an acute myeloid leukemia patient-
derived retroviral cDNA library, and showed that
JAK3
V674A can transform the lymphoid pro-B-cell line
BaF3 to IL-3-independent growth [23]. Since our com-
pound showed ability to directly inhibit JAK3 kinase
activity, treatment with the compound should block
JAK3 activity in BaF3-JAK3
V674A cells. To test this
hypothesis, we examined the effect of our compound on
JAK3 phosphorylation in BaF3-JAK3
V674A cells. In BaF3-
JAK3
WT cells, phospho-JAK3 was detected at a basal
level and was not induced by IL-3 treatment (Figure
3A), consistent with the report that IL-3 regulates the
proliferation and differentiation of hematopoietic cells
through the tyrosine phosphorylation of JAK2 and not
of JAK3 [24]. By contrast, in the absence of IL-3, persis-
tently-active JAK3 was inhibited in a dose-dependent
manner by treatment of BaF3-JAK3
V674A cells with
NSC114792 (Figure 3A). In fact, a 10 μmol/L concentra-
tion of NSC114792 significantly abolished JAK3
phosphorylation. Since treatment with our compound
led to a block in JAK3 phosphorylation in the cells, we
expected to see a decrease in the levels of phosphory-
lated STAT5, which is a key downstream target of
JAK3. Indeed, we found that the compound also inhibits
phospho-STAT5 levels in a dose-dependent manner
(Figure 3A). Since JAK3
V674A conferred IL-3-indepen-
dent growth to BaF3-JAK3
V674A cells, we reasoned that
the inhibition of this JAK3 should lead to a decrease in
the viability of these cells. As predicted, treatment with
NSC114792 decreased the viability of BaF3-JAK3
V674A
cells in a time- and dose-dependent manner (Figure 3B).
By contrast, BaF3-JAK3
WT cells showed near 100% via-
bility in the presence of IL-3, and they were impervious
to the effects of the compound, even at a 20 μmol/L
concentration. These observations suggest that the
decreased viability of BaF3-JAK3
V674A cells treated with
NSC114792 was not caused by the non-specific cyto-
toxicity of this compound. We next determined that the
IC50 value of NSC114792 in the growth of BaF3-
Figure 1 Schematic diagrams of modeling of structure-based computational database screening.( A )T h ec h e m i c a ls t r u c t u r eo f
NSC114792 (C26H32N4O2S; M.W., 464.6). Figures were generated by Pymol http://pymol.sourceforge.net. (B) Stereo structures of overlaid
staurosporine analog AFN941 (4ST) and NSC114792 with JAK3 kinase domain (PDB ID: 1YVJ). 4ST is drawn in yellow and NSC114792 in cyan. (C)
Predicted binding model of NSC114792 to the JAK3 kinase domain. Only the residues that contact NSC114792 are labeled. These contacts were
selected only when two atoms in protein and ligand are located within 3.5Å.
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V674A c e l l si s2 0 . 9μmol/L (Figure S1, Additional
file 1). To verify that our compound’s activities were not
limited to BaF3 cells, we assessed its ability to inhibit
JAK3 in pre-B leukemia cell line BKO84, which is
derived from BLNK
-/- mice [18]. BLNK is a tumor sup-
pressor that regulates IL-7-dependent survival of pre-B
cells via direct inhibition of JAK3, indicating a crucial
role of JAK3 in pre-B cell proliferation [18]. Consistent
with this, treatment of BKO84 cells with anti-IL-7R-
blocking antibody, which should decrease JAK3 activity,
resulted in decreased cell viability [18]. To evaluate the
effect of our compound on JAK3 activity in these cells,
we cultured them with various concentrations of
NSC114792. We found that treatment with NSC114792
decreased the tyrosine phosphorylation of both JAK3
and STAT5 in a dose-dependent manner (Figure 3C).
Furthermore, we found that BKO84 cells treated with
NSC114792 have significantly decreased viability in a
time- and dose-dependent manner (Figure 3D). Taken
together, our findings suggest that NSC114792 directly
binds to JAK3 and inhibits its catalytic activity.
NSC114792 blocks IL-2-induced JAK3/STAT5 signaling
JAK2 plays a pivotal role in signal transductions through
the highly related receptors for cytokines and some hor-
mones, including IL-3, prolactin (PRL), erythropoietin,
granulocyte-macrophage colony-stimulating factor, and
growth hormone [25,26]. By contrast, JAK3 is activated
through the association with only the gco fI L - 2 ,I L - 4 ,
IL-7, IL-9, IL-15 and IL-21 receptors [3,6,27]. To further
evaluate the specificity of NSC114792 for JAK3 inhibi-
tion, we used the rat pre-T lymphoma cell line Nb2 and
Figure 2 NSC114792 selectively inhibits JAK3 kinase activity in vitro. JAK1 (A), JAK2 (B), JAK3 (C), or TYK2 (D) immunoprecipitates were used
for in vitro kinase assay. Each immunoprecipitate was pre-incubated with either vehicle (DMSO) alone, NSC114792 at different concentrations or
the pan-JAK kinase inhibitor AG490 (100 μmol/L) for 1 hour. Kinase reactions were subsequently performed by the addition of recombinant
STAT3a protein as a substrate and 2 μmol/L ATP for 30 minutes at 30°C. The reaction products were processed for Western blotting and probed
with antibodies specific for phospho-STAT3, STAT3, JAK1, JAK2, JAK3, and TYK2. Note that NSC114792 blocks JAK3 kinase activity in a dose-
dependent manner but failed to inhibit the kinase activity of other JAK family members. STAT3, JAK1, JAK2, JAK3, and TYK2 serve as a loading
control.
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expressing IL-2Rb (32D/IL-2Rb), both of which have
been previously used to study cytokine-dependent acti-
vation of JAK proteins [28,29].
We first examined the effects of NSC114792 on phos-
pho-JAK2 and phospho-JAK3 induced by PRL and IL-2
treatment, respectively, in Nb2 cells. Cells were incu-
bated in the presence of NSC114792 for 16 hours and
then stimulated by PRL or IL-2 for 10 minutes. While
phospho-JAK2 and phospho-JAK3 were barely detect-
able in cells without stimulation, their levels were
increased in response to PRL and IL-2 stimulation,
respectively (Figure 4A and 4B). As expected,
NSC114792 could not inhibit PRL-induced JAK2/
STAT5 phosphorylation at the concentrations up to 20
μmol/L (Fig. 4A). By contrast, it did block IL-2-induced
JAK3/STAT5 phosphorylati o ni nad o s e - d e p e n d e n t
manner (Figure 4B). In fact, IL-2-induced phospho-
STAT5 levels were decreased by more than 80% at a 5
μmol/L of NSC114792 compared with those of control,
and undetectable at a 10 μmol/L (Figure 4B). By con-
trast, treatment of Nb2 cells with AG490 resulted in a
profound reduction of both PRL-induced JAK2/STAT5
and IL-2-induced JAK3/STAT5 phosphorylation, due to
its ability to inhibit all JAKs. The selective effect of
NSC114792 on JAK3/STAT5 signaling in Nb2 cells was
further demonstrated in 32D/IL-2Rb cells. In these cells,
JAK2 and JAK3 are activated by IL-3 and IL-2 treat-
ment, respectively [29]. Cells were treated with
NSC114792 for 16 hours and then stimulated with IL-3
Figure 3 NSC114792 affects the viability of BaF3 cells expressing an activating allele of JAK3. BaF3-JAK3
V674A cells were transformed by
introducing an activating allele of JAK3 (V674A) [23]. (A) Treatment of BaF3-JAK3
V674A cells with NSC114792 results in a decrease in
phosphorylated JAK3 and STAT5 levels in a dose-dependent manner. (B) NSC114792 decreases the viability of BaF3-JAK3
V674A cells in a time- and
dose-dependent manner. BaF3-JAK3
WT cells were incubated for the indicated time periods in the absence or presence of IL-3, and with or
without 20 μmol/L NSC114792. BaF3-JAK3
V674A cells were also cultured with NSC114792 at various concentrations for the indicated time periods.
BaF3-JAK3
WT cells showed IL-3-dependent survival, and the viability of these cells was barely affected by 20 μmol/L NSC114792. By contrast, this
dose of compound significantly decreased the viability of BaF3-JAK3
V674A cells. These data suggest that the effect of NSC114792 on BaF3-
JAK3
V674A cell viability is not caused by the non-specific cytotoxicity of the compound. (C and D) NSC114792 blocks both JAK3 and STAT5
phosphorylation, and causes a significant decrease in cell viability in BLNK
-/- mice-derived BKO84 cells, which express constitutively-active JAK3/
STAT5 due to the lack of BLNK inhibition of JAK3 [18]. (B) *, p < 0.001, indicates statistical significance compared to DMSO-treated BaF3-JAK3
V674
cells. #, p < 0.01, indicates statistical significance compared to IL-3-treated BaF3-JAK
WT cells. (D) *, p < 0.001, indicates statistical significance
compared to DMSO-treated BKO84 cells.
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absence of cytokine stimulation, phospho-JAK2 and
phospho-JAK3 were barely detectable. However, consis-
tent with the previous report, JAK2 and JAK3 become
tyrosine phosphorylated in response to treatment with
IL-3 and IL-2, respectively (Figures 4C and 4D). Consis-
tent with the results from Nb2 cells, NSC114792 did
not affect IL-3-induced JAK2/STAT5 phosphorylation
(Figure 4C), whereas it did block IL-2-induced JAK3/
STAT5 phosphorylation (Figure 4D). Once again, the
pan-JAK inhibitor AG490 non-selectively inhibited JAK2
and JAK3 phosphorylation induced by IL-3 and IL-2,
respectively. These findings strongly suggest that
NSC114792 has selectivity for JAK3 over JAK2.
NSC114792 inhibits persistently-active JAK3
We further assessed if NSC114792 can specifically inhi-
bit JAK3, but not other JAKs, using various cancer cell
lines where constitutively-active JAK kinases are
expressed. Hodgkin’s lymphoma L540 cells had high
levels of phospho-JAK3 but undetectable levels of phos-
pho-JAK1 and -JAK2 (Figure 5A). In contrast, Hodgkin’s
lymphoma HLDM-2 cells, breast cancer MDA-MB-468
cells and prostate cancer DU145 cells exhibited high
levels of phospho-JAK1 and -JAK2 but not phospho-
JAK3 (Figure 5B-D). We assessed if NSC114792 can
inhibit the persistently-active JAK kinases in these cells.
Treatment of L540 cells with NSC114792 caused a
reduction of phospho-JAK3 levels in a dose-dependent
manner, whereas this compound did not alter the total
JAK3 levels (Figure 5A, lanes 5 and 6). We found that
L540 cells treated with 10 μmol/L NSC114792 exhibited
more than a 70% decrease in the phospho-JAK3 levels,
compared with those of control. Moreover, when L540
cells were treated with 20 μmol/L NSC114792, JAK3
phosphorylation was almost completely abolished. By
contrast, the compound did not alter phospho-JAK1 and
-JAK2 levels in HDLM-2, MDA-MB-468, and DU145
cells (Figure 5B-D, lanes 1-4). In addition, NSC114792
did not inhibit IFN-a-induced TYK2 phosphorylation in
U266 cells at the concentrations up to 20 μmol/L (Fig-
ure S2, Additional file 2). As expected, AG490 pro-
foundly reduced the phosphorylation levels of all JAKs
tested in those cells (Figure 5A-D, lanes 1-6; Figure S2,
Additional file 2). Our results thus far indicate that
NSC114792 selectively inhibits JAK3. To assess the
functional outcome of this inhibition, we monitored the
phosphorylation of a JAK3 target. We chose STAT3,
which is phosphorylated by JAKs on Y705, as its persis-
tent activation is the most common STAT form found
in human cancers [30]. We found that NSC114792 inhi-
bits phospho-STAT3 levels in a dose-dependent manner
in L540 cells, which have elevated phospho-JAK3 levels
(Figure 5A, lanes 7 and 8). In contrast, at the
concentrations up to 20 μmol/L, NSC114792 did not
inhibit the phosphorylation of STAT3 in cells that lack
persistently-active JAK3 (i.e., HDLM-2, MDA-MB-468,
and DU145 cells) (Figure 5B-D, lanes 7 and 8). As pre-
dicted, treatment of all cell lines with AG490 resulted in
ad r a m a t i cd e c r e a s ei np h o s p h o - S T A T 3l e v e l si na l lc e l l
lines tested (Figure 5A-D, lanes 7 and 8).
Members of the Src family of non-receptor tyrosine
kinases can activate STAT3 by phosphorylating Y705
[31]. To assess if our compound can inhibit Src family
kinases, we monitored the tyrosine phosphorylation
state of Src and Lyn. NSC114792 did not reduce the
levels of phospho-Lyn in L540 and HDLM-2 cells or the
levels of phospho-Src in MDA-MB-468 and DU145 cells
at any concentration tested (Figure 5A-D, lanes 9-12).
We further examined whether NSC114792 can affect
other oncogenic signaling pathway components, such as
the serine/threonine kinase Akt or MAPK (also called
ERK1/2). We detected no significant inhibitory effects of
our compound on phospho-Akt and phospho-ERK1/2
levels in all cell lines tested (Figure 5A-D, lanes 13-16).
Taken together, our results indicate that NSC114792
selectively inhibits JAK3 activity and subsequently leads
to a block in STAT signaling.
NSC114792 selectively inhibits the viability of cancer cells
with constitutively-active JAK3
Small molecule inhibitors of JAK/STAT signaling have
been shown to repress cell proliferation by affecting cell
viability in a variety of solid tumor cell lines, as well as
in blood malignant cell lines, suggesting the critical role
of JAK/STAT signaling in the proliferation of cancer
cells [32-35]. Because NSC114792 selectively inhibited
JAK3/STAT signaling, we hypothesized that treatment
with our compound would affect cell viability only in
cancer cells that express constitutively-active JAK3/
STATs. We assessed if NSC114792 can reduce viability
of L540, HDLM-2, MDA-MB-468, and DU145 cells.
Cells were treated with either vehicle (DMSO) alone,
NSC114792 at different concentrations or AG490, and
they were incubated for various time periods. We found
that NSC114792 decreases cell viability only in L540
cells with persistent JAK3 activation, in a time- and
dose-dependent manner, but not in HDLM-2, MDA-
MB-468 and DU145 which lack persistently-active JAK3
(Figures 5 and 6A). In contrast, treatment with the pan-
JAK inhibitor AG490 significantly reduced cell viability
in all cell lines tested (Figure 6A).
NSC114792 induces apoptosis via down-regulating the
expression of anti-apoptotic genes
We previously reported that treatment L540 cells with
siRNA against JAK3 causes an increase in the cleavage
of PARP and caspase-3, and a decrease in the
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knockdown of JAK3 activity closely correlates with
apoptosis in L540 cells. To demonstrate that
NSC114792 affected cell viability by inducing apopto-
sis, we performed TUNEL assay on L540 cells. We
found that treatment with NSC114792 induces apopto-
sis in a dose-dependent manner in L540 cells and that
the number of TUNEL-positive cells increased more
than 30-fold in cells treated with 20 μmol/L
NSC114792 compared with controls (Figure 6B). To
gain more insights into the molecular mechanism by
which NSC114792 induces apoptosis in L540 cells, we
assessed if it can induce an increase in the cleavage of
PARP and caspase-3, both of which are hallmarks of
apoptosis [37]. As expected, treatment with the
compound increased both PARP and caspase-3 cleaved
fragments in a dose-dependent manner (Figure 6C).
We next examined the effect of this compound on the
expression of anti-apoptotic genes, which are known
STAT targets. L540 cells were treated with NSC114792
for 48 hours, and then the whole-cell extracts were
processed for Western blot analysis using antibodies
specific for Bcl-2, Bcl-xL, Mcl-1, and Survivin. The
expression of these proteins was inhibited by treatment
with NSC114792 in a dose-dependent manner, whereas
the levels of GAPDH remained unchanged (Figure 6D).
These results indicate that in L540 cells NSC114792
inhibits JAK3/STAT signaling and thus decreases cell
survival by inducing apoptosis through down-regulat-
ing the expression of anti-apoptotic genes.
Figure 4 NSC114792 inhibits IL-2-induced JAK3/STAT5 but not PRL- or IL-3-induced JAK2/STAT5 signaling. Effects of NSC114792 on
JAK2/STAT5 and JAK3/STAT5 signaling induced by PRL (prolactin) (A) and IL-2 (B), respectively, in the rat pre-T lymphoma cell line Nb2. Effects of
NSC114792 on JAK2/STAT5 and JAK3/STAT5 signaling induced by IL-3 (C) and IL-2 (D), respectively, in the murine myeloid progenitor cell line
32D stably expressing IL-2Rb (32D/IL-2Rb). These cells were starved for 16 hours in the presence of either vehicle (DMSO) alone, NSC114792 at
different concentrations, or the pan-JAK inhibitor AG490 (100 μmol/L). Nb2 cells and 32D/IL-2Rb cells were subsequently stimulated by PRL (100
ng/mL) or IL-2 (100 ng/mL) for 10 minutes, and IL-3 (5 ng/mL) or IL-2 (100 ng/mL) for 30 minutes, respectively. In Nb2 cells, NSC114792
decreased IL-2-induced phospho-JAK3 and -STAT5 levels in a dose-dependent manner, but failed to decrease PRL-induced phospho-JAK2 and
-STAT5 levels. Similarly, in 32D/IL-2Rb cells, this compound blocked IL-2-induced phospho-JAK3 and -STAT5, but was defective in inhibiting IL-3
induced phospho-JAK2 and -STAT5. AG490, a pan-JAK inhibitor, non-selectively blocked both phospho-JAK2 and -JAK3 in all cells.
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In this study, we performed a small-scale, pilot struc-
ture-based computational database screen using the
molecular docking program AutoDock (Version 4.0) for
compounds that dock into the catalytic site of JAK3
kinase domain. This screening resulted in the identifica-
tion of NSC114792 as a lead compound that specifically
inhibits the catalytic activity of JAK3 but not that of
other JAK family members. Our results indicate that the
mechanism by which NSC114792 inhibits JAK3 involves
direct interaction between this small molecule and the
JAK3 kinase domain. In vitro kinase assays revealed that
addition of this compound to the JAK3 immunoprecipi-
tates causes a significant block in JAK3 kinase activity.
Furthermore, the inhibition of JAK3 by this compound
was disrupted in the presence of excess ATP, indicating
that NSC114792 is an APT-competitive JAK3 inhibitor
(data not shown). Notably, this compound was defective
in inhibiting the kinase activity of other JAKs, even at a
concentration that almost completely abolished JAK3
kinase activity. The specificity of NSC114792 for JAK3
over other JAK kinases was further supported by our
Figure 5 NSC114792 selectively inhibits persistently-active JAK3/STAT signaling in cancer cells. The Hodgkin’s lymphoma cell lines L540
(A) and HDLM-2 (B), the breast cancer cell line MDA-MB-468 (C), and the prostate cancer cell line DU145 (D) were cultured for 24 hours in the
presence of either vehicle (DMSO) alone, NSC114792 at various concentrations up to 20 μmol/L, or the pan-JAK inhibitor AG490 (150 μmol/L).
Whole-cell extracts were processed for Western blot analysis using antibodies specific for the molecules indicated. Treatment with NSC114792
did not alter the levels of phospho-JAK1 and -JAK2 (B-D, lanes 1-4), but it did potently inhibit phospho-JAK3 in a dose-dependent manner (A,
lanes 5 and 6). Consistently, the compound decreased phospho-STAT3 only in L540 cells, which exhibit persistent JAK3 activation (lanes 7 and 8).
In contrast, AG490 non-selectively decreased the phosphorylation of JAK kinases and thus led to a block in phospho-STAT3 in all cell lines tested.
NSC114792 did not alter the levels of other activated oncogenic kinases, including phospho-Src (lanes 9 and 10), phospho-Lyn (lanes 11 and 12),
phospho-Akt (lanes 13 and14), and phospho-ERK1/2 (lanes 15 and 16). None of these kinases were affected by treatment with NSC114792 at
concentrations up to 20 μmol/L.
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Page 8 of 13docking simulation. Of the homologous sequences that
were retrieved by BLAST search based on the sequence
of JAK3 kinase domain (1YVG), we identified five with
reported structures. The PDB codes of these are: 3EYG
and 3EYH for JAK1 kinase, and 2B7A, 3E62 and 3FUP
for JAK2 kinase. We attempted the docking simulation
of NSC114792 toward these structures. We found the
value of dissociation constant, Kd, calculated by Auto-
Dock energy for 1YVG/NSC114792 (i.e., JAK3) was 5.44
nM. By contrast, the dissociation constants were: 40.25
nM (3EYG/NSC114792) and 18.68 nM (3EYH/
NSC114792) for JAK1; and 17.47 nM (2B7A/
NSC114792), 18.82 nM (3E62/NSC114792), and 36.95
nM (3FUP/NSC114792) for JAK2. These observations
suggest that the binding affinity of NSC114792 to the
JAK3 kinase domain is at least 3-fold higher to those of
JAK1 and JAK2. We next performed a detailed analysis
to seek for possible reasons for the high selectivity of
NSC114792 for JAK3 over other JAK kinases. We com-
pared the ligand-binding pockets in all JAK proteins and
superimposed the ligand structures onto the pockets.
Our analysis showed that the purine moiety of
NSC11492 fits snugly into a cleft comprised of Ala-829,
Lys-831, Glu-847, Val-860, Met-878, Ala-942, Asp-943
and Phe-944 in JAK3 kinase domain. While most of
these residues are conserved in JAK1, JAK2 and JAK3,
Ala-942 is unique to JAK3. In JAK1 and JAK2, a Gly
residue is found in the analogous position of Ala-942.
We found that the methyl group of Ala-942 forms
hydrophobic contacts with the purine moiety of
NSC114792. To examine the role of the methyl group
on Ala-942-NSC114792 interactions, we performed in
Figure 6 NSC114792 decreases cell viability and induces apoptosis in cancer cells with persistent JAK3 activation. (A) NSC114792
decreases cell viability only in L540 cells that express persistently-active JAK3. L540, HLDM-2, MDA-MB-468 and DU145 cells were treated with
either vehicle (DMSO) alone, NSC114792 at different concentrations or the pan-JAK inhibitor AG490, and incubated for the indicated time
periods. The trypan blue exclusion assay was performed to count viable cells. Results are shown as the mean of three independent experiments
(± SD indicated by error bar). *, p < 0.001, indicates statistical significance compared to DMSO-treated cells. (B) TUNEL assay shows that
NSC114792 induces apoptosis in L540 cells. Cells were treated with vehicle (DMSO) alone or NSC114792 at various concentrations for 72 hours.
Cells were then stained with FITC-conjugated BrdU antibody and propidium iodide (PI), and subsequently subjected to flow cytometry. The
percentages of TUNEL-positive cells are indicated. (C and D) Treatment with NSC114792 increases cleaved fragments of Poly (ADP-ribose)
polymerase (PARP) and caspase-3, and decreases the expression of anti-apoptotic genes in a dose-dependent manner in L540 cells. Cells were
treated with vehicle (DMSO) alone or NSC114792 at various concentrations for 48 hours. Whole-cell extracts were processed for Western blot
analysis using antibodies specific for the molecules indicated. GAPDH serves as a loading control.
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Page 9 of 13silico docking experiments on a JAK3 kinase domain in
which Ala-942 was mutated to Gly. Interestingly, the
calculated binding free energy between NSC114792 and
JAK3 kinase domain dropped from 5.44 nM to 74.16
nM. This observation suggests that Ala-942 in the JAK3
kinase domain is the key residue determining the speci-
ficity of NSC114792 for JAK3. To demonstrate the
selectivity of NSC114792 for JAK3, we also showed that
NSC114792 inhibits the tyrosine phosphorylation of
JAK3 and decreases cell viability only in cancer cells
harboring persistently-activated JAK3. The reduced cell
viability is likely due to a decrease in the expression of
anti-apoptotic genes because treatment of L540 cells
with NSC114792 resulted in a significant increase in the
apoptosis and a concomitant decrease in the expression
of Bcl-2, Bcl-xL and other factors that block pro-
grammed cell death. By contrast, this compound had no
effect on cancer cells that lack persistently-activated
JAK3. Interestingly, our compound did not alter the
levels of phosphorylated forms of other oncogenic
kinases, such as Src, Akt and ERK1/2. Although the spe-
cificity of NSC114792 for JAK3 over other oncogenic
kinases still needs to be fully examined by evaluating its
effects on a large panel of tyrosine and serine/threonine
kinases in vitro, our findings strongly suggest that it
selectively inhibits JAK3.
Recent studies identified somatic mutations of JAK3 in
a minority of acute megakaryoblastic leukemia patients
[7-10], in a high-risk childhood acute lymphoblastic leu-
kemia case [11], and in cutaneous T-cell lymphoma
patients [12]. Importantly, functional analyses of many
of those identified JAK3 mutations showed that each of
the mutations can transform BaF3 cells to factor-inde-
pendent growth and can cause lethal hematopoietic
malignancies in murine bone marrow transplantation
models [7], suggesting that somatic JAK3 mutations
contribute to the pathogenesis of various hematopoietic
malignancies. These findings strongly demonstrate that
JAK3 can serve as a logical target for therapeutic inter-
vention in the hematopoietic malignancies with activat-
ing alleles of JAK3. In contrast to the role of gain-of-
function of JAK3 in the pathogenesis of hematopoietic
malignancies, JAK3 deficiency in mice and human
causes immunodeficiency, indicating the pivotal role of
JAK3 in the immune system [6,38,39]. In fact, recently
developed JAK3 inhibitors, including CP-690550,
PNU156804 and R348, can function as immunosuppres-
sive agents [40-42]. These compounds have been shown
to inhibit cytokine-induced JAK3 activity and signifi-
cantly prolong survival in animal models for organ
transplantations. Taken together, small molecule inhibi-
tors that can selectively block JAK3 activity may have
enormous therapeutic value in several immune-related
diseases including organ allograft rejection, as well as in
lymphoproliferative disorders with aberrant JAK3
activation.
Conclusions
As the protein structure determination methodology
advances, the use of a structure-based drug discovery
approach is becoming more popular due to the possibi-
lity to screen millions of molecules in a timely way [43].
NSC114792, a novel small molecule identified through
structure-based computational database screen, potently
inhibits both cytokine-induced and constitutively-active
JAK3. Importantly, this compound exhibited selectivity
for JAK3 over other JAK family members and other
oncogenic signaling pathway components. These results
indicate the robustness and validity of our structure-
based virtual screen.
Finally, our study strongly suggests that NSC114792
or its derivatives can be used as a lead compound to
develop new group of drugs targeting JAK3, and may
have therapeutic potential in human immune-related
diseases and hematopoietic malignancies that are caused
by aberrant JAK3 activity.
Methods
Structure-based virtual screen
To discover compounds that inhibit JAK3 activity, we
employed AutoDock version 4 [44] and performed vir-
tual screening with the NCI diversity set of compounds.
The protein coordinate from the complex structure
(PDB ID: 1YVJ) between the JAK3 kinase domain and
its inhibitor staurosporine analog AFN941 (4ST) [45]
was chosen for virtual screening. After removing the
ligand and solvent molecules from the complex struc-
ture, hydrogen atoms were added. Ionizable states in
Asp, Glu, His, and Lys residues were considered by PDB
2PQR[46]. The docking simulation of a compound starts
with defining 3D potential grids for the receptor protein
against the atom types of a compound. The calculated
grid maps were of dimension 40 × 40 × 40 points with
the spacing of 0.375 Å. For the parameters of generic
algorithm in AutoDock version 4, we used 100 and
500,000 for the number of individuals in population
(ga_pop_size) and the maximum number of generations
(ga_num_evals), respectively. A docking for each com-
pound was repeated 10 times with different initial con-
formations that were generated by AMBER [47], and the
conformations and energies in the 10 runs were clus-
tered together. All the procedures in the virtual screen-
ing were carried out in automatic way using in-house
written scripts. As proof of principle, we assessed if 4ST,
a known substrate of JAK3, could bind to the kinase
domain using our method. The docked conformation of
4ST was in excellent agreement with the bound confor-
mation in the crystal structure, showing the pairwise
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Page 10 of 13root mean square deviation value of 0.70 Å. Once com-
pleting virtual screen, the final results were ranked on
the bases of the predicted binding free energy and the
cluster size for each docking conformation.
NSC114792
NSC114792 is one of the compounds identified from the
NCI diversity set of compounds, which have been
deposited to the Developmental Therapeutics Program
(DTP)/NCI by the outside originators of the materials
and have been available to investigators for non-clinical
research purposes. The infor m a t i o no nt h es y n t h e s i so f
NSC114792 and its purity is not available from the
DTP/NCI website at the time of re-submission.
Cell lines and culture conditions
The Hodgkin’s lymphoma cell lines L540 and HLDM-2
were obtained from the German Collection of Microor-
ganisms and Cell Cultures (DSMZ, Germany) and main-
tained in RPMI 1640 containing 20% FBS. The breast
cancer cell line MDA-MB-468, the prostate cancer cell
line DU145 and the multiple myeloma cell line U266
were purchased from the American Type Culture Col-
lection (Rockville, MD). MDA-MB-468 and DU145 cells
were maintained in DMEM containing 10% FBS, and
U266 cells were maintained in RMPI1640 containing
10% FBS. Bone marrow-derived pro-B-cell line BaF3 sta-
bly expressing wild type JAK3 or mutant JAK3 (V674A)
were obtained from Dr. Hiroyuki Mano [23] and main-
tained in RPMI 1640 containing 10% FBS. Pre-T lym-
phoma Nb2 cells were obtained from Dr. Charles V.
Clevenger [48], and cultured in RPMI 1640 containing
10% FBS and 5 mM HEPES buffer, pH 7.3. Myeloid pro-
genitor 32D cells stably expressing IL-2Rb were
obtained from Drs. Achsah D. Keegan and Warren J.
Leonard [49,50], and maintained in RPMI 1640 medium
containing 10% FBS and 5% WEHI-3B cell-conditioned
medium as a source of IL-3. BKO84 cells were cultured
in RPMI1640 containing 10% FBS, 55 μM2 - M E ,a n d
500 μg/mL G418 [18]. All the cells were cultured at 37°
C in a humidified incubator containing 5% CO2.
Western blot analysis and antibodies
Cell pellets were lysed in a lysis buffer [50 mM Tris-
HCl, pH 7.4, 350 mM NaCl, 1% Triton X-100, 0.5%
Nonidet P-40, 10% glycerol, 0.1% SDS, 1 mM EDTA, 1
mM EGTA, 1 mM Na3VO4, 1 mM phenylmethylsulpho-
nyl fluoride, and phosphatase inhibitor cocktail]. Whole-
cell extracts were resolved on SDS-PAGE, transferred to
nitrocellulose membrane, and probed with appropriate
antibodies. Antibodies specific for phospho-JAK3, JAK3,
STAT3, STAT5 and Lyn were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibodies speci-
fic for phospho-STAT3, phospho-STAT5, JAK1,
phospho-JAK2, JAK2, phospho-TYK2, TYK2, phospho-
Src, Src, phospho-Lyn, phospho-Akt, Akt, phospho-
ERK1/2, ERK1/2, PARP, caspase-3, Bcl-2, Bcl-xL, Mcl-1,
Survivin and GAPDH were purchased from Cell Signal-
ing Technology (Cambridge, MA). Phospho-JAK1 anti-
body was obtained from Upstate Chemicon (Temecula,
CA). Membranes were blocked in 5% non-fat dried milk
in Tris-buffered saline containing 0.1% Tween 20 for 1
hour and subsequently incubated with primary antibo-
dies at 4°C for overnight. Membranes were then probed
with horseradish peroxidase-conjugated secondary anti-
bodies (GE Healthcare, Piscataway, NJ), and then visua-
lized by Enhanced Chemiluminescence Reagent (GE
Healthcare, Piscataway, NJ).
Cell viability and apoptosis assay
Cell viability was determined by the trypan blue exclu-
sion assay. Briefly, cells (5 × 10
4 cells/mL) were treated
with either vehicle (DMSO) alone, NSC114792 at differ-
ent concentrations or AG490 (100 μmol/L), and incu-
bated for the indicated time periods. For performing
apoptosis assay, TUNEL assay was conducted as pre-
viously described [36]. Briefly, L540 cells (1.0 × 10
6
cells/mL) were treated with either vehicle (DMSO)
alone or NSC114792 (10 or 20 μmol/L) for 72 hours,
stained using an APO-BRDU™ kit, according to the
manufacture’s protocol (Phoenix Flow Systems, San
Diego, CA), and then subsequently subjected to Elite
ESP flow cytometry (Coulter Inc., Miami, FL).
In vitro kinase assay
Recombinant His-tagged STAT3a protein was purified
as previously described [36] and used as a substrate for
in vitro kinase assays. For in vitro JAK kinase assays,
L540, HDLM-2 and IFN-a-stimulated U266 cells were
lysed in a lysis buffer [20 mM Tris-HCl (pH 7.4), 500
mM NaCl, 0.25% Triton X-100, 1 mM EDTA, 1 mM
EGTA, 10 mM b-glycerophosphate, 1 mM DTT, 300
μMN a 3VO4, 1 mM phenylmethylsulphonyl fluoride,
and phosphatase inhibitor cocktails] on ice. The lysates
were pre-cleared with protein A/G-sepharose for 2
hours at 4°C and then incubated with anti-JAK1, anti-
JAK2, anti-JAK3 or TYK2 antibodies for overnight at 4°
C. The immune complexes were subsequently precipi-
tated by protein A/G-sepharose beads. The precipitates
were washed twice with kinase buffer [25 mM Tris/HCl
(pH 7.5), 20 mM b-glycerophosphate, 10 mM MgCl2,2
mM DTT, 1 mM Na3VO4, and protease inhibitor cock-
tail]. The immune complexes were mixed with either
vehicle (DMSO) alone, NSC114792 at different concen-
trations or the pan-JAK inhibitor AG490 for 1 hour at
30°C. Kinase reactions were subsequently performed by
the addition of 2 μg His-tagged STAT3a proteins in the
a b s e n c eo rp r e s e n c eo fA T P( 2μmol/L) for 30 minutes
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PAGE and probed with antibodies specific for phospho-
STAT3, STAT3, JAK1, JAK2, JAK3, or TYK2.
Additional file 1: Figure S1 - NSC114792 inhibits cell growth in
BaF3-JAK3
V674A cells. BaF3-JAK3
V674A cells were treated with either
vehicle (DMSO) alone or NSC114792 at various concentrations up to 40
μmol/L, and incubated for 48 hours. Note that the IC50 value of
NSC114792 is 20.9 μmol/L. Results are shown as the mean of three
independent experiments (± SD indicated by error bar). *, p < 0.001.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-36-
S1.JPEG]
Additional file 2: Figure S2 - Treatment with NSC114792 has no
effect on TYK2 phosphorylation. U266 cells were cultured for 24 hours
in the presence of either vehicle (DMSO) alone, NSC114792 at different
concentrations or the pan-JAK inhibitor AG490 (150 μmol/L), and then
stimulated with 1000 U/mL IFN-a for 30 minutes. Whole-cell extracts
were processed for Western blot analysis using phospho-TYK2 and TYK2
antibodies. GAPDH serves as a loading control.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-36-
S2.JPEG]
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